Who Paid My Doc
Peter Staats
Pain Medicine Shrewsbury, NJ Medical Doctor
NPI 1013909340 CMS profile 227778
160 Avenue At The Cmn, Suite 1, Shrewsbury, NJ 07702
General payments
$285,908
Research payments
$116,200
Ownership & investment interest
$419,530
Research they led as principal investigator
$11,700
Through program year 2025, Peter Staats of Shrewsbury, NJ is reported in the CMS Open Payments database as having received $285,908 across 253 general payments and $116,200 in research payments paid to them. Separately, studies naming them as principal investigator received $11,700 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $419,530 across 7 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
18 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $50,563 | 49 | |
| 2024 | General | $62,929 | 71 | |
| 2023 | General | $73,744 | 49 | |
| 2022 | General | $29,486 | 33 | |
| 2022 | Research | $24,250 | 11 | |
| 2021 | General | $29,516 | 17 | |
| 2021 | Research | $19,729 | 5 | |
| 2020 | General | $36,820 | 20 | |
| 2020 | Research | $72,081 | 5 | |
| 2019 | General | $2,850 | 14 | |
| 2019 | Research | $140 | 1 | |
| 2025 | Ownership | $64,805 | 1 | |
| 2024 | Ownership | $64,805 | 1 | |
| 2023 | Ownership | $64,805 | 1 | |
| 2022 | Ownership | $64,805 | 1 | |
| 2021 | Ownership | $64,805 | 1 | |
| 2020 | Ownership | $64,805 | 1 | |
| 2019 | Ownership | $30,700 | 1 |
Beside peers
- Peter Staats
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Peter Staats were reported at $50,563. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.
Show as a table
| Year | Peter Staats | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,850 | $498 | $126–$1,682 | $163 |
| 2020 | $36,820 | $284 | $80–$910 | $114 |
| 2021 | $29,516 | $399 | $112–$1,219 | $132 |
| 2022 | $29,486 | $455 | $137–$1,484 | $149 |
| 2023 | $73,744 | $484 | $128–$1,495 | $160 |
| 2024 | $62,929 | $498 | $131–$1,540 | $164 |
| 2025 | $50,563 | $458 | $124–$1,401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
275 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pain Medicine in New Jersey
Related records
Pain Medicine in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.